Trial · NCT04737187
Adverse events326
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 326
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutrophil count decreased | Investigations | Trifluridine/Tipiracil + Bevacizumab | 34 | 246 | |
| other | Neutrophil count decreased | Investigations | Trifluridine/Tipiracil | 18 | 246 | |
| other | Platelet count decreased | Investigations | Trifluridine/Tipiracil + Bevacizumab | 24 | 246 | |
| other | Platelet count decreased | Investigations | Trifluridine/Tipiracil | 6 | 246 | |
| other | Alanine aminotransferase increased | Investigations | Trifluridine/Tipiracil + Bevacizumab | 20 | 246 | |
| other | Alanine aminotransferase increased | Investigations | Trifluridine/Tipiracil | 14 | 246 | |
| other | Aspartate aminotransferase increased | Investigations | Trifluridine/Tipiracil + Bevacizumab | 20 | 246 | |
| other | Aspartate aminotransferase increased | Investigations | Trifluridine/Tipiracil | 14 | 246 | |
| other | Weight decreased | Investigations | Trifluridine/Tipiracil + Bevacizumab | 23 | 246 | |
| other | Weight decreased | Investigations | Trifluridine/Tipiracil | 12 | 246 | |
| other | Blood bilirubin increased | Investigations | Trifluridine/Tipiracil + Bevacizumab | 16 | 246 | |
| other | Blood bilirubin increased | Investigations | Trifluridine/Tipiracil | 14 | 246 | |
| other | Hypertension | Vascular disorders | Trifluridine/Tipiracil + Bevacizumab | 26 | 246 | |
| other | Hypertension | Vascular disorders | Trifluridine/Tipiracil | 5 | 246 | |
| other | Headache | Nervous system disorders | Trifluridine/Tipiracil + Bevacizumab | 21 | 246 | |
| other | Headache | Nervous system disorders | Trifluridine/Tipiracil | 9 | 246 | |
| other | Neutropenia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 153 | 246 | |
| other | Neutropenia | Blood and lymphatic system disorders | Trifluridine/Tipiracil | 126 | 246 | |
| other | Anaemia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 79 | 246 | |
| other | Anaemia | Blood and lymphatic system disorders | Trifluridine/Tipiracil | 80 | 246 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04737187/events